The direct effects of propofol on myocyte contractile function after hypothermic cardioplegic arrest.
Propofol is being used more often in cardiac surgery, particularly after hypothermic, hyperkalemic cardioplegic arrest (HHCA). The purpose of this study was to examine the effects of propofol on isolated myocyte contractile function under both normothermic conditions and after simulated HHCA and rewarming. Myocytes were isolated from the left ventricle of eight pigs. Myocyte contractile function was measured under both normothermic conditions and after simulated HHCA (incubation at 4 degrees C for 2 h in crystalloid cardioplegia; K+ = 24 mEq/L) using computer-assisted videomicroscopy in the presence of 2, 4, and 6 micrograms/mL propofol (11.2, 22.4, and 33.6 microM/L, respectively). Isoproterenol (25 nM) was then added and contractile function measurements repeated. Propofol caused significant dose-dependent reductions in myocyte velocity of shortening (baseline = 67 +/- 2 microns/s; propofol = 2 micrograms/mL, 45 +/- 4 microns/s; and propofol = 6 micrograms/mL, 27 +/- 3 microns/s; P < 0.05). HHCA and rewarming caused a significant reduction in myocyte velocity of shortening (29 +/- 0.9 microns/s, P < 0.05), with further significant dose-dependent reductions in contractile function after the addition of propofol. Propofol caused a decrease in beta-adrenergic responsiveness under normothermic conditions, but not after simulated HHCA. Results from the present study demonstrated for the first time that the reduction in isolated myocyte contractile function after simulated HHCA is further decreased by propofol administration.
Department of Anesthesia and Perioperative Medicine, Medical University of South Carolina, Charleston 29425-2207, USA.
L
L
Hebbar
B H
BH
Dorman
R C
RC
Roy
F G
FG
Spinale
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D018686:Anesthetics, Intravenous / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D002314:Cardioplegic Solutions / Q000008:administration & dosage; D002478:Cells, Cultured; D000077324:Crystalloid Solutions; D004305:Dose-Response Relationship, Drug; D006321:Heart / Q000187:drug effects*; D006324:Heart Arrest, Induced; D007036:Hypothermia, Induced; D007091:Image Processing, Computer-Assisted; D007545:Isoproterenol / Q000494:pharmacology; D007552:Isotonic Solutions; D018715:Microscopy, Video; D009200:Myocardial Contraction / Q000187:drug effects*; D009206:Myocardium / Q000473:pathology*; D010952:Plasma Substitutes / Q000008:administration & dosage; D011188:Potassium / Q000008:administration & dosage; D015742:Propofol / Q000008:administration & dosage / Q000494:pharmacology*; D017694:Rewarming; D013552:Swine; D016277:Ventricular Function, Left
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D018686:Anesthetics, Intravenous; D002314:Cardioplegic Solutions; D000077324:Crystalloid Solutions; D007552:Isotonic Solutions; D010952:Plasma Substitutes; D007545:Isoproterenol; D011188:Potassium; D015742:Propofol